Status:

RECRUITING

Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.

Lead Sponsor:

University of Sao Paulo General Hospital

Collaborating Sponsors:

InCor Heart Institute

Conditions:

Chagas Cardiomyopathy

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

Chagas disease is considered by the World Health Organization (WHO) as one of the most neglected tropical diseases in the world, having relevance in many Latin America countries. In addition, it alrea...

Detailed Description

Introduction: Chagas disease (CD) is an infectious parasitic disease caused by the protozoan Trypanosoma cruzi. It is considered by the World Health Organization (WHO) as one of the most neglected tro...

Eligibility Criteria

Inclusion

  • Positive serology for Chagas;
  • Age \> 18 years old;
  • New York Heart Association (NYHA) heart failure and functional class II, III or IV;
  • Left ventricular ejection fraction \<40% at least in the last 3 months;
  • Patients using a beta-blocker with stable dose (last 4 weeks) and optimized;
  • Patients using ACEI or ARB with a stable dose (last 4 weeks) and optimized.

Exclusion

  • Participants who do not agree to participate in the study
  • Participants who do not want to receive sacubitril/ valsartan medication;
  • Patients with symptomatic hypotension;
  • Patients with systolic blood pressure (SBP) lower than 95 mmHg on randomization;
  • Patients with creatinine clearance (ClCr) less than 30 mL/min;
  • Patients with serum potassium \> 5.2 mmol/L;
  • Patients with a history of angioedema or who experienced severe side effects with ACE inhibitors.

Key Trial Info

Start Date :

May 6 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2024

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT04853758

Start Date

May 6 2021

End Date

December 1 2024

Last Update

April 4 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Heart Institute (Incor) University of Sao Paulo

São Paulo, Brazil, 05403000